A Study Assessing KB407 for the Treatment of Cystic Fibrosis

A Study in Adult and Pediatric Patients With Cystic Fibrosis

NCT00034515 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Safety and Efficacy of Inhaled OligoG CF-5/20 for the Treatment Cystic Fibrosis

NCT00970346 ·Status: COMPLETED ·Phase: PHASE1

Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacodynamics of QBW251 in Healthy Subjects and Cystic Fibrosis Patients

NCT02190604 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

Inhaled Therapy Adherence and Outcomes to Kaftrio in Cystic Fibrosis

NCT05519020 ·Status: COMPLETED

Phase 1b Safety, Tolerability, and PK Study to Assess GS-5737 in Subjects With CF

NCT01840735 ·Status: COMPLETED ·Phase: PHASE1

Infant Study of Inhaled Saline in Cystic Fibrosis

NCT00709280 ·Status: COMPLETED ·Phase: NA

A Study to Evaluate the Safety and Efficacy of VX-371 in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation

NCT02709109 ·Status: COMPLETED ·Phase: PHASE2

Dose Escalation Study of KB001 in Cystic Fibrosis Patients Infected With Pseudomonas Aeruginosa

NCT00638365 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

A Study to Confirm the Long-term Safety and Effectiveness of Kalydeco in Patients With Cystic Fibrosis Who Have an R117H-CFTR Mutation, Including Pediatric Patients

NCT02722057 ·Status: COMPLETED

Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of QBW251 in Subjects With Bronchiectasis

NCT04396366 ·Status: TERMINATED ·Phase: PHASE2

Safety and Tolerability Trial of Inhaled Alpha1-Proteinase Inhibitor (Human), Hydrophobic Chromatography Process (Alpha-1 HC) in Subjects With Cystic Fibrosis

NCT01684410 ·Status: COMPLETED ·Phase: PHASE2

Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy Participants

NCT07283770 ·Status: RECRUITING ·Phase: PHASE1

Study to Evaluate the Safety of CB-280 in Patients With Cystic Fibrosis

NCT04279769 ·Status: COMPLETED ·Phase: PHASE1

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QAU145 in Patients With Cystic Fibrosis

NCT00506792 ·Status: COMPLETED ·Phase: PHASE2

Study of Safety, Tolerability & Efficacy in Cystic Fibrosis Patients With Abnormal Glucose Tolerance

NCT02955888 ·Status: TERMINATED ·Phase: PHASE2

A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF

NCT06237335 ·Status: RECRUITING ·Phase: PHASE2

A Study to Assess the Pharmacokinetics and Safety of Co-administered Oral Galicaftor, Navocaftor, and ABBV-576 in Healthy Adults for the Treatment of Cystic Fibrosis

NCT05530278 ·Status: COMPLETED ·Phase: PHASE1

A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)

NCT05668741 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2

Study of Denufosol Tetrasodium in Patients With Cystic Fibrosis Lung Disease

NCT00103714 ·Status: COMPLETED ·Phase: PHASE2

Inhaled Mannitol on Mucociliary Clearance in Moderate to Severe Cystic Fibrosis

NCT05740618 ·Status: COMPLETED ·Phase: PHASE4

Researching the Effects of Airway Clearance Therapies in Cystic Fibrosis

NCT03078127 ·Status: COMPLETED ·Phase: NA

A Phase 1 Trial to Assess the Safety, Tolerability, and Pharmacokinetics of GS 9411 in Subjects With Cystic Fibrosis (CF)

NCT01025713 ·Status: WITHDRAWN ·Phase: PHASE1

Study to Evaluate Safety and Efficacy of VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation With an Open-Label Expansion

NCT02070744 ·Status: COMPLETED ·Phase: PHASE2

Taking Advantage of Phage Technologies (TAPT) to Facilitate Phage Therapy While Reducing the Use of Antibiotics in the Management of Cystic Fibrosis (CF)

NCT07048704 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1

Tolerability of Hypertonic Saline in Infants With Cystic Fibrosis

NCT00753987 ·Status: COMPLETED ·Phase: PHASE1